GlassScriptPhysician profile
David L Stockman
NPI 1407086424
$23,564.96
in general payments reported to CMS, 2019-2025
26 companies · $174 in 2025
The $174 reported for 2025 was less than what a typical Dermatopathology (Dermatology) provider received nationally (typical 2025 total: $251).
See the full distribution for Dermatopathology (Dermatology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $68.47 · 2020: $78.44 · 2021: $220 · 2022: $475 · 2023: $486 · 2024: $22K · 2025: $174.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $21K · Food and Beverage: $1,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $21,456.19 |
| Food and Beverage | $1,267.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $21,558.34 | 2022-2024 | Bf-Rhodoled, Rhodoled Xl, Ameluz |
| Novartis Pharmaceuticals Corporation | $659.50 | 2021-2024 | |
| Pfizer INC. | $268.83 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $163.60 | 2022-2025 | Spevigo, Cyltezo |
| Myriad Genetic Laboratories, INC. | $147.80 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $86.22 | 2021-2024 | Dupixent |
| Genzyme Corporation | $72.53 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $70.16 | 2023-2025 | Zoryve |
| Stemline Therapeutics INC. | $65.10 | 2020 | |
| Amgen INC. | $59.92 | 2024 | Otezla |
| Organon LLC | $56.05 | 2025 | Hadlima |
| Janssen Biotech, INC. | $41.05 | 2022-2023 | Tremfya |
| Radius Health, INC. | $39.37 | 2023 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $27.93 | 2023-2024 | Sotyktu |
| Ucb, INC. | $26.47 | 2024 | Bimzelx |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $25.67 | 2022 | |
| Springworks Therapeutics, INC. | $24.54 | 2025 | Gomekli |
| Bioventus LLC | $24.04 | 2022 | |
| Smith+Nephew, INC. | $22.85 | 2021 | |
| Xeris Pharmaceuticals, INC. | $21.20 | 2024 | Gvoke Hypopen |
| Sobi, INC | $21.18 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.70 | 2024 | Saphnelo |
| Leo Pharma INC. | $16.20 | 2025 | Adbry |
| Beckman Coulter, INC. | $16.00 | 2019 | |
| Fresenius Kabi USA, LLC | $15.54 | 2023 | Idacio |
| Verrica Pharmaceuticals INC. | $15.17 | 2024 | Ycanth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Stockman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.